Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions DOI
Shamar Young, Jack Hannallah,

Dan Goldberg

et al.

Seminars in Interventional Radiology, Journal Year: 2023, Volume and Issue: 40(06), P. 515 - 523

Published: Dec. 1, 2023

Abstract In the past several decades, major advances in both systemic and locoregional therapies have been made for many cancer patients. This has led to modern treatment algorithms frequently calling active interventions by multiple subspecialists at same time. One of areas where this can be clearly seen is concomitant use patients with primary or secondary cancers liver. These combined gained favor over last decade are largely focused on allure ability control disease while time addressing refractory/resistant clonal populations. While general concept likely only increase popularity continued establishment viable immunotherapy treatments, questions remain. Lingering concerns toxicity when combining methods, patient selection, sequencing remain further work remains, some these addressed literature. article reviews available data three commonly treated liver, namely, hepatocellular carcinoma, cholangiocarcinoma, metastatic colorectal cancer. Furthermore, strengths weaknesses reviewed future directions discussed.

Language: Английский

Advances in Molecular Medicine: Unravelling Disease Complexity and Pioneering Precision Healthcare DOI Open Access
Stephen A. Bustin, K. A. Jellinger

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(18), P. 14168 - 14168

Published: Sept. 16, 2023

The escalating impacts of the climate crisis, zoonotic spill-over, and antibiotic resistance have positioned molecular medicine at forefront pioneering translational research [...].

Language: Английский

Citations

23
Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study DOI Creative Commons
Chengxiang Guo, Weibo Du, Yiwen Chen

et al.

Cancer Medicine, Journal Year: 2025, Volume and Issue: 14(3)

Published: Feb. 1, 2025

ABSTRACT Introduction Standard treatments provide limited benefits for patients with intermediate‐ or advanced‐stage hepatocellular carcinoma (HCC). This retrospective observational study aimed to assess the potential improvements in outcomes associated systemic therapies receiving transarterial chemoembolization (TACE) initially unresectable HCC. Methods Between February 2019 and March 2023, we reviewed diagnosed intermediate‐to‐advanced HCC who were treated either TACE combined antiangiogenic agents immune checkpoint inhibitors (combination therapy) as their initial treatment. To address confounding biases, further stratified into surgical non‐surgical cohorts, separate analyses conducted. The primary endpoints progression‐free survival (PFS) overall (OS), safety profiles also evaluated. Results Among 279 intermediate advanced HCC, 156 successfully underwent curative‐intent liver resection after preoperative (TACE group, n = 69; combination 87), while 123 continued 31; 92). After propensity score matching, 26 matched patient pairs generated within cohort. group exhibited significantly improved PFS compared (9.4 vs. 7.2 months, p 0.043). Cox proportional hazards analysis confirmed that therapy was (hazard ratio 0.476, 95% confidence interval: 0.257–0.883, 0.019). For exceeding up‐to‐seven criteria, demonstrated superior median (18.0 14.6 0.03) OS (not reached 50.1 0.049) group. Adverse events manageable, no treatment‐related fatalities reported. Conclusion Combination enhanced particularly higher tumor burdens.

Language: Английский

Citations

0
Thermal Ablation in the Liver: Heat versus Cold—What Is the Role of Cryoablation? DOI
Donna D’Souza,

Ranjan Ragulojan,

Chunxiao Guo

et al.

Seminars in Interventional Radiology, Journal Year: 2023, Volume and Issue: 40(06), P. 491 - 496

Published: Dec. 1, 2023

Abstract Cryoablation is commonly used in the kidney, lung, breast, and soft tissue, but an uncommon choice liver where radiofrequency ablation (RFA) microwave (MWA) predominate. This part for historical reasons due to serious complications that occurred with open hepatic cryoablation using early technology. More current technology combined image-guided percutaneous approaches has ameliorated these issues allowed become a safe effective thermal modality treating tumors. several advantages over RFA MWA including ability visualize ice ball, minimal procedural pain, strong immunomodulatory effects. article will review literature on of primary secondary tumors, focus efficacy, safety, immunogenic potential. Clinical scenarios when it may be more beneficial use heat-based liver, as well directions future research, also discussed.

Language: Английский

Citations

2
Survival Analysis of TACE Monotherapy vs. Combination Therapy in BCLC B and C Stage Hepatocellular Carcinoma: A Retrospective Cohort Study DOI Creative Commons
Chengxiang Guo, Weibo Du, Yiwen Chen

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 21, 2024

Abstract Introduction Standard treatments provide limited benefits for patients with intermediate or advanced hepatocellular carcinoma (HCC). This retrospective observational study aimed to assess potential improvements associated systemic therapies in receiving transarterial chemoembolization (TACE) initially unresectable HCC. Methods Between February 2019 March 2023, we reviewed diagnosed intermediate- to-advanced HCC, treated either TACE combined antiangiogenic and immunotherapy (combination group) as their initial treatment. To balance the impact of confounding biases, further divided entire population into surgical non-surgical cohorts conducted separate assessments. The analysis focused on comparing progression-free survival (PFS), overall (OS) safety profile combination group those monotherapy. Results Out 279 156 successfully underwent subsequent curative intent liver resection after preoperative (TACE group, n = 69, 87), while 123 continued 31, 92). After PSM, 26 matched patient pairs were generated cohort. exhibited a significantly extended PFS (9.4 vs. 7.2 months, p 0.043). Cox also suggested that this therapy regimen was improved cohort (HR 0.476, 95% CI: 0.257–0.883, 0.019). In exceeding up-to-seven criteria, demonstrated superior median (18.0 14.6 0.03) OS (Not reached 50.1 0.049) compared group. Adverse events manageable did not result any treatment-related fatalities. Conclusion antitumor particularly among higher tumor burden.

Language: Английский

Citations

0
Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions DOI
Shamar Young, Jack Hannallah,

Dan Goldberg

et al.

Seminars in Interventional Radiology, Journal Year: 2023, Volume and Issue: 40(06), P. 515 - 523

Published: Dec. 1, 2023

Abstract In the past several decades, major advances in both systemic and locoregional therapies have been made for many cancer patients. This has led to modern treatment algorithms frequently calling active interventions by multiple subspecialists at same time. One of areas where this can be clearly seen is concomitant use patients with primary or secondary cancers liver. These combined gained favor over last decade are largely focused on allure ability control disease while time addressing refractory/resistant clonal populations. While general concept likely only increase popularity continued establishment viable immunotherapy treatments, questions remain. Lingering concerns toxicity when combining methods, patient selection, sequencing remain further work remains, some these addressed literature. article reviews available data three commonly treated liver, namely, hepatocellular carcinoma, cholangiocarcinoma, metastatic colorectal cancer. Furthermore, strengths weaknesses reviewed future directions discussed.

Language: Английский

Citations

0